Aug 25, 2009 - Protalix BioTherapeutics, Inc., announced today that it has received Fast Track Designation from the U.S. FDA for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
The details can be read here.
No comments:
Post a Comment